Abstract
Purpose: Immune-mediated diseases affect millions of people worldwide with an economic impact measured in the billions of dollars. Mesenchymal stem cells (MSCs) are being investigated in the treatment of certain immune mediated diseases, but their application in the treatment of the majority of these disorders remains largely unexplored. Keratoconjunctivitis sicca can occur as a result of progressive immune-mediated destruction of lacrimal tissue in dogs and humans, and immune-mediated joint disease is common to both species. In dogs, allogeneic MSC engraftment and migration have yet to be investigated in vivo in the context of repeated injections. Methods: With these aims in mind, the engraftment of allogeneic canine MSCs after an injection into the periocular and intra-articular regions was followed in vivo using magnetic resonance and fluorescent imaging. Results: The cells were shown to be resident near the site of the injection for a minimum of 2 weeks. Analysis of 61 tissues demonstrated preferential migration and subsequent engraftment of MSCs in the thymus as well as the gastrointestinal tract. These results also detail a novel in vivo imaging technique and demonstrate the differential spatial distribution of MSCs after migration away from the sites of local delivery. Conclusion: The active engraftment of the MSCs in combination with their previously documented immunomodulatory capabilities suggests the potential for therapeutic benefit in using MSCs for the treatment of periocular and joint diseases with immune involvement.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 307-317 |
| Number of pages | 11 |
| Journal | Journal of Ocular Pharmacology and Therapeutics |
| Volume | 28 |
| Issue number | 3 |
| DOIs | |
| State | Published - Jun 1 2012 |
Fingerprint
ASJC Scopus subject areas
- Pharmacology (medical)
- Ophthalmology
- Pharmacology
Cite this
Periocular and intra-articular injection of canine adipose-derived mesenchymal stem cells : An in vivo imaging and migration study. / Wood, Joshua; Chung, Dai Jung; Park, Shin Ae; Zwingenberger, Allison; Reilly, Christopher M.; Ly, Irene; Walker, Naomi J.; Vernau, William; Hayashi, Kei; Wisner, Erik R; Cannon, Matthew S.; Kass, Philip H; Cherry, Simon R; Borjesson, Dori L; Russell, Paul; Murphy, Christopher J.
In: Journal of Ocular Pharmacology and Therapeutics, Vol. 28, No. 3, 01.06.2012, p. 307-317.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Periocular and intra-articular injection of canine adipose-derived mesenchymal stem cells
T2 - An in vivo imaging and migration study
AU - Wood, Joshua
AU - Chung, Dai Jung
AU - Park, Shin Ae
AU - Zwingenberger, Allison
AU - Reilly, Christopher M.
AU - Ly, Irene
AU - Walker, Naomi J.
AU - Vernau, William
AU - Hayashi, Kei
AU - Wisner, Erik R
AU - Cannon, Matthew S.
AU - Kass, Philip H
AU - Cherry, Simon R
AU - Borjesson, Dori L
AU - Russell, Paul
AU - Murphy, Christopher J
PY - 2012/6/1
Y1 - 2012/6/1
N2 - Purpose: Immune-mediated diseases affect millions of people worldwide with an economic impact measured in the billions of dollars. Mesenchymal stem cells (MSCs) are being investigated in the treatment of certain immune mediated diseases, but their application in the treatment of the majority of these disorders remains largely unexplored. Keratoconjunctivitis sicca can occur as a result of progressive immune-mediated destruction of lacrimal tissue in dogs and humans, and immune-mediated joint disease is common to both species. In dogs, allogeneic MSC engraftment and migration have yet to be investigated in vivo in the context of repeated injections. Methods: With these aims in mind, the engraftment of allogeneic canine MSCs after an injection into the periocular and intra-articular regions was followed in vivo using magnetic resonance and fluorescent imaging. Results: The cells were shown to be resident near the site of the injection for a minimum of 2 weeks. Analysis of 61 tissues demonstrated preferential migration and subsequent engraftment of MSCs in the thymus as well as the gastrointestinal tract. These results also detail a novel in vivo imaging technique and demonstrate the differential spatial distribution of MSCs after migration away from the sites of local delivery. Conclusion: The active engraftment of the MSCs in combination with their previously documented immunomodulatory capabilities suggests the potential for therapeutic benefit in using MSCs for the treatment of periocular and joint diseases with immune involvement.
AB - Purpose: Immune-mediated diseases affect millions of people worldwide with an economic impact measured in the billions of dollars. Mesenchymal stem cells (MSCs) are being investigated in the treatment of certain immune mediated diseases, but their application in the treatment of the majority of these disorders remains largely unexplored. Keratoconjunctivitis sicca can occur as a result of progressive immune-mediated destruction of lacrimal tissue in dogs and humans, and immune-mediated joint disease is common to both species. In dogs, allogeneic MSC engraftment and migration have yet to be investigated in vivo in the context of repeated injections. Methods: With these aims in mind, the engraftment of allogeneic canine MSCs after an injection into the periocular and intra-articular regions was followed in vivo using magnetic resonance and fluorescent imaging. Results: The cells were shown to be resident near the site of the injection for a minimum of 2 weeks. Analysis of 61 tissues demonstrated preferential migration and subsequent engraftment of MSCs in the thymus as well as the gastrointestinal tract. These results also detail a novel in vivo imaging technique and demonstrate the differential spatial distribution of MSCs after migration away from the sites of local delivery. Conclusion: The active engraftment of the MSCs in combination with their previously documented immunomodulatory capabilities suggests the potential for therapeutic benefit in using MSCs for the treatment of periocular and joint diseases with immune involvement.
UR - http://www.scopus.com/inward/record.url?scp=84862212113&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84862212113&partnerID=8YFLogxK
U2 - 10.1089/jop.2011.0166
DO - 10.1089/jop.2011.0166
M3 - Article
C2 - 22175793
AN - SCOPUS:84862212113
VL - 28
SP - 307
EP - 317
JO - Journal of Ocular Pharmacology and Therapeutics
JF - Journal of Ocular Pharmacology and Therapeutics
SN - 1080-7683
IS - 3
ER -